These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2717572)

  • 61. [Collagen content of the thyroid tissue and/urinary hydroxyproline in various forms of goiter].
    Guseĭnov IA
    Probl Endokrinol (Mosk); 1981; 27(5):20-4. PubMed ID: 6895255
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Functional reserves of the thyroid gland in thyrotoxicosis remission].
    Nosova LG; Potin VV; Khramtsova VIa
    Probl Endokrinol (Mosk); 1980; 26(3):3-6. PubMed ID: 7403026
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Scintigraphy for risk stratification of iodine-induced thyrotoxicosis in patients receiving contrast agent for coronary angiography: a prospective study of patients with low thyrotropin.
    Fricke E; Fricke H; Esdorn E; Kammeier A; Lindner O; Kleesiek K; Horstkotte D; Burchert W
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6092-6. PubMed ID: 15579763
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The prevalence of transient thyrotoxicosis after antithyroid drug therapy in patients with Graves' disease.
    Kubota S; Takata K; Arishima T; Ohye H; Nishihara E; Kudo T; Ito M; Fukata S; Amino N; Miyauchi A
    Thyroid; 2008 Jan; 18(1):63-6. PubMed ID: 18302519
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Concentration of protein-bound iodine in blood plasma in thyrotoxicosis at the early postoperative period and the effect of neuroleptoanalgesia].
    Pastukhov NA
    Probl Endokrinol (Mosk); 1977; 23(1):32-5. PubMed ID: 846973
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [HLA antigens in diffuse toxic goiter].
    Dedov II; Polozkova NI; Polianskaia IS; Efuni SS
    Probl Endokrinol (Mosk); 1991; 37(1):4-5. PubMed ID: 2027866
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The Influence of Diffuse Nontoxic Goiter on the State of Protective Mechanisms of the Oral Cavity in Children.
    Godovantes OI; Kitsak TS; Vitkovsky OO; Kuzniak LV; Godovantes OS; Chaikovska NM; Fedoniuk LY
    J Med Life; 2020; 13(1):21-25. PubMed ID: 32341696
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [The clinical laboratory manifestations of severe form of diffuse toxic goiter].
    Farkhutdinova LM; Allaberdina DU; Gaĭsarova GA; Biglova GA; Kruglova OI; Guseva PS; Mazherina LIa; Khamitov AA; Kashaev MSh; Poliakov IV; Bakiev IM
    Klin Lab Diagn; 2012 Apr; (4):44-6. PubMed ID: 22768719
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Toxic goitre in the middle-aged and elderly.
    WHISHAW R
    Med J Aust; 1946 Oct; 2(15):519-21. PubMed ID: 21002520
    [No Abstract]   [Full Text] [Related]  

  • 70. [Scintigram observations in benign non-toxic and toxic goiter].
    FOLDES J; MEGYESI K; KRASZNAI I
    Orv Hetil; 1963 Mar; 104():450-3. PubMed ID: 13945745
    [No Abstract]   [Full Text] [Related]  

  • 71. Diagnosis and treatment of toxic goiter.
    FOWLER EF
    Am Pract Dig Treat; 1948 Sep; 3(1):15-23. PubMed ID: 18881230
    [No Abstract]   [Full Text] [Related]  

  • 72. The present status of the treatment of toxic goiter.
    BLACK BM
    Miss Valley Med J; 1947 Oct; 69(4):143-8. PubMed ID: 20265285
    [No Abstract]   [Full Text] [Related]  

  • 73. Comparison between clinical and histological diagnosis in toxic and atoxic goiter, with special regard to Kraus's staining method.
    DAHLSTDT S
    Acta Chir Scand; 1947 Oct; 96(2):185-97. PubMed ID: 20271715
    [No Abstract]   [Full Text] [Related]  

  • 74. DECLINE in mortality from toxic goiter.
    Stat Bull Metropol Life Insur Co; 1947 Nov; 28(11):8-10. PubMed ID: 18918359
    [No Abstract]   [Full Text] [Related]  

  • 75. [Development of diffuse toxic goiter in the presence of prior hypothyroidism].
    Strongm LG; Korneva KG; Petrov AV; Nekrasova EA; Podupeiko NZ; Sarantsev BV; Orlinskaya NY; Tarasova NI; Soldatova YV
    Probl Endokrinol (Mosk); 2007 Jun; 53(3):38-41. PubMed ID: 31627686
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Level 2 Accrediation: A Mythbuster.
    Clarke J; Patel D
    Prim Dent J; 2020 Mar; 9(1):16-18. PubMed ID: 32519604
    [No Abstract]   [Full Text] [Related]  

  • 77. [Effect of merkazolyl on the level of thyrostimulating immunoglobulins of the blood in patients with diffuse toxic goiter].
    Oleĭnik VA; Khalangot ND
    Probl Endokrinol (Mosk); 1989; 35(1):32-5. PubMed ID: 2717572
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Dynamics of thyrostimulating immunoglobulin levels during treatment of diffuse toxic goiter].
    Sviridenko NIu; Mkrtukova NA; Kraĭnova SI; Nefedov SB; Kandror VI
    Probl Endokrinol (Mosk); 1991; 37(1):15-7. PubMed ID: 1674150
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [The effect of mercasolyl on immunologic indicators in patients with diffuse toxic goiter].
    Epishin AV; Solomko LD; Epishina NA; Kuz'mich IuP
    Vrach Delo; 1989 Feb; (2):11-4. PubMed ID: 2711649
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Experience using lithium carbonate in the complex treatment of diffuse toxic goiter].
    Petrov NM
    Ter Arkh; 1985; 57(12):32-6. PubMed ID: 3937256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.